Alpha-MSH comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
==== December ==== On 1 December, the National Guard detained 10 people, including Sheikh Raed al-Matni, Assem Abou Fakher, Ghandi Abou Fakher, Maher Falhout, Hussam Zeidan, Zeidan Zeidan and Alameddine Zeidan, clarifying that they carried out a “swift and precise” operation to arrest what it called “traitors and conspirators”. On 3 December, Sheikh Raed al-Matni's body was found with signs of torture, after being accused of having links with the Syrian government and Suleiman Abdul Baqi. The National Guard also raided al-Baqi's house, and promised a strong response. Sheikh Maher Falhout was also killed. The National Guard was reportedly behind the killings. On 8 December, the National Guard reported mortar and drone attacks by the Syrian government forces, the affected areas are: Tel Hadid, Al-Maamel road and the Kanaker area. The National Guard declared that "the hostile fire and sources of fire were extinguished and full control of the situation on the field was restored". On 15 December, the National Guard killed the poet Anwar al-Shaer, due to their criticism of the group, in Busan, Suwayda, he was taken to the Suweida National Hospital. His brother stated that "In a cowardly and treacherous operation, the martyr of the word of truth, Anwar Fawzat Al-Shaer, the free national revolutionary poet, was murdered in front of his house" and swore revenge.
Department of Defense in 2012, when the devices were not yet commercially available and therefore did not require FDA approval. FDA inspection reports from 2014 and 2015 stated that its containers for blood collection were "not validated under actual or simulated use conditions" and "were not reviewed and not approved by designated individual(s) prior to issuance". In 2015, an FDA inspection resulted in multiple observed violations of FDA Title 21 Regulations. It was eventually revealed that the FDA had classified Theranos's device, called a nanotainer, as a Class II medical device, meaning that Theranos would need to use special labels, meet certain performance standards and perform post-market surveillance of the device. Theranos asserted that the nanotainer was a Class I medical device and therefore not subject to any regulatory requirements. After the 2015 inspection, Theranos announced that it would voluntarily suspend its tests apart from the FDA-approved herpes simplex virus (HSV-1) test. The Arizona Department of Health Services reported issues with the company's Scottsdale lab meeting regulations in September 2015. The reports were revealed in the Arizona Republic in November 2015. In January 2016, the Centers for Medicare and Medicaid Services (CMS) sent a letter to Theranos based on a 2015 inspection of its Newark, California lab, reporting that the facility caused "immediate jeopardy to patient health and safety" due to a test to determine the correct dose of the blood-thinning drug warfarin.
=== Deconvolution of libraries cleaved from the solid support === If the synthesized molecules of a combinatorial library are cleaved from the solid support, a soluble mixture forms. In such solution, millions of different compounds may be found. When this synthetic method was developed, it first seemed impossible to identify the molecules, and to find molecules with useful properties. Strategies for identification of the useful components have been developed, however, to solve this problem. All these strategies are based on synthesis and testing of partial libraries. An early iterative strategy was devised by Furka in 1982. The method was later independently published by Erb et al. under the name "Recursive deconvolution"
Sources: en.wikipedia.org
It was scheduled for release in August 2000 but canceled by the publisher Sierra Entertainment by this time. As Kudirka reported to id Software that he had been taken off a project, the studio referred him to the director Steven Spielberg. His company DreamWorks SKG had experimented with developing a personal computer follow-up to Medal of Honor but decided to work with an external partner instead. In May 2000, 2015 began work on what became Medal of Honor: Allied Assault. According to Kudirka, shortly before the release of Allied Assault, the studio director of development Vince Zampella began secretly meeting with Electronic Arts to establish a separate studio and take over most staff. Out of 27 employees, 20 had resigned by the end of the month. Zampella and Jason West founded Infinity Ward, which ultimately hired 22 former 2015 staffers. Rieke, who also left, said the development team had bonded but sought to work under a different management. In response to the departures, Kudirka filed a lawsuit against Zampella, which was settled when Activision bought a 30% stake in Infinity Ward. Allied Assault was a critical and commercial success, selling 1.5 million copies within a year. In January 2003, Vivendi Universal Games announced Men of Valor as 2015's next game for Windows and the Xbox. By March, 2015 had grown to 39 people, with John Whitmore as the new director of development. Men of Valor, released in 2004, was not as commercially successful as Allied Assault and subsequent attempts to pitch games to publishers failed.
Some other researchers were more optimistic. AI pioneer Jürgen Schmidhuber did not sign the joint statement, emphasising that in 95% of all cases, AI research is about making "human lives longer and healthier and easier." While the tools that are now being used to improve lives can also be used by bad actors, "they can also be used against the bad actors." Andrew Ng also argued that "it's a mistake to fall for the doomsday hype on AI—and that regulators who do will only benefit vested interests." Yann LeCun, a Turing Award winner, disagreed with the idea that AI will subordinate humans "simply because they are smarter, let alone destroy [us]", "scoff[ing] at his peers' dystopian scenarios of supercharged misinformation and even, eventually, human extinction." In contrast, he claimed that "intelligent machines will usher in a new renaissance for humanity, a new era of enlightenment." In the early 2010s, experts argued that the risks are too distant in the future to warrant research or that humans will be valuable from the perspective of a superintelligent machine. However, after 2016, the study of current and future risks and possible solutions became a serious area of research. Some have argued that concerns about existential risks of AI could draw attention away from other AI risks.
anti-fascists persons crucial for industries those married to ethnic Czechs It is estimated that between 700,000 and 800,000 Germans were affected by "wild" expulsions between May and August 1945. The expulsions were encouraged by Czechoslovak politicians and were generally carried out by the order of local authorities, mostly by groups of armed volunteers. However, in some cases it was initiated or pursued by assistance of the regular army. The expulsion according to the Potsdam Conference proceeded from 25 January 1946 until October of that year. An estimated 1.6 million ethnic Germans were deported to the American zone of what would become West Germany. An estimated 800,000 were deported to the Soviet zone (in what would become East Germany). Several thousand died violently during the expulsion and many more died from hunger and illness as a consequence. These casualties include violent deaths and suicides, deaths in internment camps and natural causes. The joint Czech-German commission of historians stated in 1996 the following numbers: The deaths caused by violence and abnormal living conditions amount to approximately 10,000 persons killed. Another 5,000–6,000 people died of unspecified reasons related to expulsion making the total number of victims of the expulsion 15,000–16,000 (this excludes suicides, which make another approximately 3,400 cases). Approximately 225,000 Germans remained in Czechoslovakia, of whom 50,000 emigrated or were expelled soon after.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.